Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (Q36005648)

11 August 2017

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials (English)

1 reference

11 August 2017

phase III clinical trial

0 references

Nick C Fox

10

0 references

Reisa Sperling

4

object named as

Reisa Sperling

1 reference

11 August 2017

Enchi Liu

1

1 reference

11 August 2017

Mark E Schmidt

2

1 reference

11 August 2017

Richard Margolin

3

1 reference

11 August 2017

Robert Koeppe

5

1 reference

11 August 2017

Neale S Mason

6

1 reference

11 August 2017

William E Klunk

7

1 reference

11 August 2017

Chester A Mathis

8

1 reference

11 August 2017

Stephen Salloway

9

1 reference

11 August 2017

Derek L Hill

11

1 reference

11 August 2017

Andrea S Les

12

1 reference

11 August 2017

Peter Collins

13

1 reference

11 August 2017

Keith M Gregg

14

1 reference

11 August 2017

Jianing Di

15

1 reference

11 August 2017

Yuan Lu

16

1 reference

11 August 2017

I Cristina Tudor

17

1 reference

11 August 2017

Bradley T Wyman

18

1 reference

11 August 2017

Kevin Booth

19

1 reference

11 August 2017

Stephanie Broome

20

1 reference

11 August 2017

Eric Yuen

21

1 reference

11 August 2017

Michael Grundman

22

1 reference

11 August 2017

H Robert Brashear

23

1 reference

11 August 2017

Bapineuzumab 301 and 302 Clinical Trial Investigators

24

1 reference

11 August 2017

language of work or name

English

0 references

publication date

24 July 2015

1 reference

11 August 2017

1 reference

11 August 2017

85

1 reference

11 August 2017

8

1 reference

11 August 2017

692-700

1 reference

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

LoAd: a locally adaptive cortical segmentation algorithm

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Nonrigid registration using free-form deformations: application to breast MR images

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Design and construction of a realistic digital brain phantom

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Pathological verification of ischemic score in differentiation of dementias.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

Fast free-form deformation using graphics processing units.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4553028

10.1212/WNL.0000000000001877

23 September 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

26208959

1 reference